Serono Symposia International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so participants may form their own judgments, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement, nor a recommendation, on the part of Serono Symposia International Foundation. All presentations solely represent the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Frederik Barkhof: Declared receipt of honoraria or consultation fees from UCB, Schering, Sanofi-Aventis, Novartis, Roche and SSIF.

Giancarlo Comi: Declared receipt of honoraria or consultation fees from Serono Symposia International Foundation, Biogen-Dompé, Novartis, Bayer-Schering, Teva Pharmaceutical Ind. and Sanofi Aventis.

Bruce A.C. Cree: Declared receipt of grants and contracts from BioMS (Lily), EMD Serono, Genentech and honoraria or consultation fees from Biogen Idec and Teva Neurosciences.

Renaud A. Du Pasquier: Declared receipt of honoraria or consultation fees from Merck Serono, Biogen Dompé and Sanofi Aventis.

Mark S. Freedman: Declared receipt of honoraria or consultation fees from Bayer, BiogenIdec, BioMS Merck Serono, Novartis, Sanofi-Aventis, Teva. Declared also to be a member of a Bayer, BiogenIdec, BioMS Merck Serono, Novartis and Sanofi Aventis advisory boards or other similar groups.

Gavin Giovannoni: Declared receipt of personal compensation received for participating on advisory boards in relation to clinical trial design, trial steering committees and data and safety monitoring committees, from Bayer-Schering Healthcare, Biogen-Idec, Merck-Serono, Novartis, Teva-Aventis and UCB Pharma. Declared also personal compensation received for serving as a grant reviewer from Irish Science Foundation. Declared receipt of research support from Bayer-Schering Healthcare, Biogen-Idec, Merck Serono, Merz, Novartis and Teva-Aventis.

Hans-Peter Hartung: Declared receipt of honoraria or consultation fees from BiogenIdec and Novartis. Declared also to be a member of a Bayer Schering and Teva advisory boards or other similar groups.

Letizia Leocani: Declared no potential conflict of interest.

Fred D. Lublin: Declared receipt of Sources of Funding for Research from Acorda Therapeutics Inc., Biogen Idec, Genentech Inc., Novartis Pharmaceuticals Corp, Teva Neuroscience Inc., Genzyme and Sanofi-Aventis. Declared receipt of consulting Agreements/Advisory Boards/DSMB from Bayer HealthCare Pharmaceuticals, Biogen Idec, BioMS Medical Corporation, EMD Serono Inc., Genetech Inc., Novartis, Pfizer, Teva Neuroscience, Genmab, Medicinova, Actelion and Allozyne. Declared participation in Speakers’ Bureau/Honorarium Agrements from EMD Serono, Pfizer and Teva Neuroscience. Declared also current financial interests/stock ownership in Cognition Pharmaceuticals Inc.

Mar Tintoré: Declare receipt of grants and contracts and honoraria or consultation fees from Bayer-Schering, Biogen-Idec, Merck Serono, Teva, Sanofi-Aventis and Novartis.

Sandra Vukusic: Provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off-label) uses of drugs as of July 22, 2009.